Objective: The ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP came at high costs, and its economy is not clear. Therefore, this study aimed to evaluate the cost-effectiveness of SEP from the perspective of the Chinese healthcare system.
Design: A partition survival model was built to simulate the outcomes. The clinical data came from the ASTRUM-005 trial, and only direct medical costs were included in the model. The utility values referred to the published literature. Scenario analyses 1 and 2 explored outcomes in the presence of a patient assistance plan (PAP) and different simulation periods, respectively. Scenario analysis 3 compared the cost-effectiveness of atezolizumab plus chemotherapy (AEP) with SEP by network meta-analysis. Sensitivity analyses were conducted to assess the robustness of the results.
Outcome Measures: Total costs, incremental costs, life years, quality-adjusted life years (QALYs), incremental QALYs and incremental cost-effectiveness ratio (ICER).
Results: Compared with chemotherapy, SEP achieved an additional 0.34 QALYs at incremental costs of US$41 682.63, with an ICER of US$122 378.86/QALY. When PAP was available, ICER was US$58 316.46/QALY. In the simulation time of 5 years and 20 years, the ICER was US$132 637.97/QALY and US$118 054.59/QALY, respectively. When compared with AEP, SEP not only reduced the costs by US$47 244.87 but also gained 0.07 QALYs more. Sensitivity analyses showed that the price of serplulimab and the utility value of the progression-free survival stage were the main influencing parameters, and the results were stable.
Conclusions: Compared with chemotherapy, SEP was not cost-effective from the perspective of the Chinese healthcare system. However, SEP was absolutely dominant in comparison with AEP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432650 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2023-072106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of neoadjuvant chemoradiotherapy in T4 rectal cancer patients: a real-world single institution experience.
Radiat Oncol J
December 2024
Department of Radiation Oncology, Cancer Research Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: Treatment outcomes of locally advanced rectal cancer have improved significantly in recent decades. This retrospective study aimed to assess the efficacy of neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with T4 rectal cancer and the different outcomes between T4a and T4b patients.
Materials And Methods: A total of 60 clinically T4 rectal cancer patients who underwent nCRT were included in the analysis.
Olig2 single-colony-derived cranial bone-marrow mesenchymal stem cells achieve improved regeneration in a cuprizone-induced demyelination mouse model.
J Zhejiang Univ Sci B
September 2024
Center for Rehabilitation Medicine, Department of Neurosurgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
Article Synopsis
- Oligodendrocytes, the myelinating cells in the central nervous system, are often damaged during brain injuries and neurodegenerative diseases, leading to conditions like multiple sclerosis (MS), which is characterized by myelin loss and neurological deficits.
- Current MS treatments mainly focus on reducing relapses in the early stages but do not cure the disease or help during its progressive phase, especially in more severe cases.
- Mesenchymal stem cells (MSCs) show promise for regenerative medicine due to their ability to differentiate into neural cells and their low risk for complications, with recent studies exploring their effectiveness in treating demyelination in a mouse model.
Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2- Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia.
Breast J
January 2025
Department of Oncology University Hospital Center Split School of Medicine University of Split, Split, Croatia.
Article Synopsis
- The study focuses on the challenges of managing disease recurrence in early-stage hormone receptor-positive (HR+), HER2-negative breast cancer due to its biological complexity and the presence of PIK3CA mutations.
- Approximately 30-40% of advanced HR+/HER2- breast cancer patients have PIK3CA mutations, which are linked to poor prognosis by activating pathways that promote cell growth.
- The research found that patients with the PIK3CA mutation, particularly the H1047 variant, had a lower risk of disease recurrence compared to those without the mutation, suggesting its potential as a biomarker for personalized treatment strategies.
Medially Based "Abdominal Rotation Advancement Flap": A Promising Technique for Mastectomy Defect Reconstruction in "High-Risk Patients" Awaiting Adjuvant Radiotherapy.
Indian J Plast Surg
December 2024
Department of Plastic Surgery, Osmania Medical College, Telangana, India.
Extensive postmastectomy defects and soft-tissue defects often require some additional flap cover of reconstruction after excision. The reconstruction aim in this group should be a diligent and easy closure with a quality skin cover, early recovery, and brief stay in hospital so that the patients can receive early postoperative radiotherapy/chemotherapy. Medially based abdominal transposition flap is a type C fasciocutaneous flap based on medial perforating vessels.
View Article and Find Full Text PDFDevelopment and Validation of a Stability-Indicating High-Performance Liquid Chromatography Method Coupled With a Diode Array Detector for Quantifying Haloperidol in Oral Solution Using the Analytical Quality-by-Design Approach.
J Sep Sci
January 2025
Department of Pharmacy, Pharmaceutical Sciences Postgraduate Research Program, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
This study developed a stability-indicating HPLC-DAD method for quantifying haloperidol in oral solution using analytical quality-by-design principles. Haloperidol stability was tested under acidic, alkaline, oxidative, and photolytic stress conditions. The analytical quality-by-design approach began by defining the analytical target profile and identifying critical material attributes and critical method parameters via risk analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!